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Abstract 
 
Background: Single-nucleotide polymorphisms (SNPs) of TP53 (codon 72, rs1042522) 
and MDM2 promoter (SNP 309, rs2279744) have been associated with risk for various 
human cancers. However, studies analyzing these polymorphisms in pancreatic ductal 
adenocarcinoma (PDAC) are lacking.  
 
Methods: We investigated TP53 codon 72 and MDM2 SNP 309 polymorphisms in 32 
patients with PDAC, 16 patients with chronic pancreatitis (CP), and 32 normal controls, 
using formalin-fixed paraffin-embedded tissue. We also examined TP53 and MDM2 
protein immunohistochemistry (IHC) to assess the involvement of these differences in 
malignant transformation and disease progression. 
 
Results:  TP53 Pro/Pro genotype was significantly more frequent in PDAC patients 
than in controls (65.6 vs. 15.6%, p < 0.001) and no significant difference was found 
between CP patients (37.5%) and controls. In MDM2 SNP 309, there were no 
significant differences among the three groups. Based on the Kaplan-Meier analysis, 
overall survival was significantly shorter in MDM2 G/G genotypes compared with other 
genotypes (G/T and T/T) (359 vs. 911 days, p = 0.016) whereas no significant 
differences in TP53 genotypes were observed (638 vs. 752 days, p = 0.471). Although 
TP53 IHC was frequent in PDAC patients (53.1%), TP53 and MDM2 protein 
expression was not correlated with polymorphisms.  
 
Conclusion: Our study demonstrated TP53 codon 72 polymorphism is potentially a 
genetic predisposing factor while MDM2 SNP 309 polymorphism might be useful in 
predicting survival outcome. 
